What is BioNews Services? BioNews Services is the only digital publication for the latest, in-depth news covering 30 (and growing) chronic disease education and clinical trial disease specific websites. Our credibility is based on original and consistently updated editorial primarily written by Ph.D. educated authors. That's why BioNews earns industry-leading engagement throughout the global healthcare community, reaching a 100% targetable audience of patients, caregivers, physicians and industry professionals, through disease-dedicated websites and social media platforms.

Not just a website, a network of news-based patient education platforms

Over 90 internet properties currently operating

1

Disease specific, fact-based, continuous updates on their chronic disease is a passion for patients and caregivers because information provides them a level of control and power over their lives

Easy to access, targeted clinical trial audience

3

Our expertise

Publishing accurate, insightful news daily that builds authority for our sites among patient populations that translates into increased conversions for our clients.

Getting new information into the hands of our audience in near real-time

Building a community of visitors who trust our content

Research and publication of highly relevant news across multiple therapeutic areas targeted to patients, caregivers, healthcare providers and industry professionals

Speed – mobilizing on unprecedented timelines

Grassroots approach to building company awareness with patients, healthcare providers, industry or the investor community

!!

Leveraging social media to the greatest extent in order to provide the most HIGHLY TARGETED outreach possible in today’s patient recruitment space

5

Our unique approach

We employ a fully HIPAA compliant recruiting process with the ability to segment patients according to inclusion / exclusion criteria

Our content ranks at or near the top in Google News in all therapeutic areas and is increasing in prominence in organic Google searches

We leverage social media to deliver our content to people who have expressed an interest in a particular topic

Our team publishes over 40 original content news articles each day which are posted to therapeutic-specific URLs owned by BioNews Services

We include clinical trial advertisements within the body of our publications

!!

We demo- and geographically target the desired patient population providing no “wasted” views / impressions on our content and ads

5

Our difference

80+ % of our readers do not visit WebMD for updates on their indication according to our reader surveys

Recent reader surveys across a number of BioNews sites indicates that greater than 85% of our readers trust the information on BioNews

BioNews doesn’t rely on static pay per click or sidebar ads to attract visitors. Patients don’t engage with or share ads with their network. They engage with and share content that is meaningful to their quality of life

Highly engaged readers – more than 70% of readers visit our sites at least twice per week with 57% visiting more than 3 times per week

!!

Due to the niche focus of our content and its relevance to our audience, BioNews sites realize click through rates far above industry averages

We reach patients that are not performing simple Google searches about their disease thereby not exposed to Google PPC ads

The audience

5

Upon entering a new therapeutic area, BioNews quickly becomes the leading publisher of news related to the condition. We publish, on average, 20 original content articles per month for each of our sites.

Sites are indexed into Google News and surrounded by a multichannel social media presence which includes:

•  Facebook •  Twitter •  Pinterest •  Tumblr •  Google+ •  LinkedIn The robust nature of our publishing platform positions each site as an authority within the Google News framework. We regularly achieve 6 – 10 page one search results in Google News.

Where does traffic come from?

Visitor acquisition platforms

Link Sharing

Tumblr

VISITOR ACQUISITION

Search

Facebook

Pinterest Twitter

8

Reddit!

Social media

7

Social Media, namely Facebook, allows users to create profiles where they can identify themselves with certain interests. In addition, Facebook constantly gathers data on what each user views, clicks, shares, likes, reads, re-posts, etc… resulting in more detailed profiles.

Our news-based model has proven to be extremely effective with the patient and caregiver communities on social media, resulting in significant levels of community engagement. Our pages regularly experience the highest levels of engagement across all disease specific pages on the Facebook platform.

Outside of organic reach, we are able to build sophisticated campaigns that allow us to deliver our branded content to these highly-targeted audiences. This insures that key patient and caregiver demographics are exposed to and engaging with our content.

Where does traffic come from part 2?

8

38% Almost 40% of visitors to BioNews sites are outside of the United States. Our reach is truly global allowing clients to leverage the power of our disease education platforms without geographic limitations. We work closely with top translation companies and can design a campaign to serve any patient population the world over.

Global reach

Our process

•  Prepare dedicated news website and begin synthesis of current news and research relevant to sponsor and/or patients in therapeutic area

•  Analyze social media

outlets and patient profile databases to establish target parameters for identifying potential patients to be targeted

•  Introduce concept to

investigative sites

PLAN CREATE LAUNCH REPORT

9

•  Fully optimize the

content platform around disease-specific keyword research and analytics

•  Design study-specific

ads (“buttons”) to insert into sites and articles

•  Generate unique

clinician- and patient-friendly news content (building the community)

•  Create trial registry survey and/or trial map as a supplementary page of the news site

•  Aggressively push

news articles to targeted audiences and direct traffic to conversion pages

•  Launch outreach

campaign and begin metric tracking and analytics (following IRB approval)

•  Regular reporting to sponsor of all relevant metrics (visits, clicks, conversions, etc..)

Our sites

10

ALSNewsToday.com!AlzheimersNewsToday.com!BioNews-TX.com!BreastCancer-News.com!BronchiectasisNewsToday.com!CardiovascularDiseaseNews.com!CataractNewsToday.com!ColonCancerNewsToday.com!CysticFibrosisNewsToday.com!DiabetesNewsJournal.com!

FibromyalgiaNewsToday.com!FriedreichsAtaxiaNews.com!HepatitisNewsToday.com!IBDNewsToday.com!Immuno-OncologyNews.com!LungCancerNewsToday.com!LungDiseaseNews.com!LupusNewsToday.com!MelanomaNewsToday.com!MitochondrialDiseaseNews.com

MultipleSclerosisNewsToday.com!MuscularDystrophyNews.com!ObesityNewsToday.com!ProstateCancerNewsToday.com!PulmonaryFibrosisNews.com!PulmonaryHypertensionNews.com!RadiationTherapyNews.com!RheumatoidArthritisNews.com!SclerodermaNews.com!SMANewsToday.com!

Our sites Homepage, article page with trial ads

11

Our sites Map page with pins and associated contact form

12

Our sites Location specific landing page with contact form

13

Through custom sitemaps, geo-targeted ads and social media targeting, BioNews can deliver deliver content and recruitment conversion opportunities to patients in a specific geographic region

Optimal tactic for under performing sites that need a boost in patient flow or for sites with aggressive investigators who are motivated to enroll

Campaign launch timeline

WEEK 1 WEEK 2 WEEK 3 WEEK 4 WEEK 5

•  Secure URL •  Build website

•  Create associated Social Media accounts

•  Social media and keyword analysis

•  Begin publishing articles

•  Provide program outline to sites for IRB approval

•  Complete outline of trial map

•  Continued publishing and community building

•  Submit site application to Google News

•  Continue publishing news in therapeutic area

•  Begin development of social media communities

•  Finalize ad / button design

•  Launch full program for Central IRB sites

•  Begin pushing content to target demographic

•  Begin gathering

analytics / metrics

14

What we measure

1. Website activity Visits, Pageviews, time on site, etc…

2. Ad engagement Impressions, click through

rate

3. Social media engagement Shares, likes, comments, favorites, retweets, etc…

4. Campaign outcomes Map / questionnaire views, time on page, forms submitted, randomizations

18

Metrics we report

Lorem ipsum dolor sit amet, consectetur adipiscing

ANA de BARROS, PhD

ANA TAN, R.N.

CHARLES MOORE MAUREEN NEWMAN

Managing Editor

Managing Editor

Contributing Editor Sr. Science Columnist

DANIELA SEMEDO, PhD Sr. Science Columnist

Dr. Ana de Barros has worked as a postdoctoral researcher at Instituto de Medicina Molecular in Lisbon, Portugal. She graduated with a BS in Genetics from the University of Newcastle and received her Masters in Biomolecular Archaeology from the University of Manchester, England. She earned her PhD in immunotherapy at the University of Lisbon.

Anna Tan is a Registered Nurse, and brings her direct experience in working with patients to her role as a Managing Editor at BioNews Services. Since her task is to source, assign, and edit articles on our news platform daily, Anna works to synthesize science and research news into concise, easy-to-understand stories that are accessible to patients.

Charles Moore is a syndicated columnist for several major Canadian print newspapers and has an extensive background in covering technology. He serves as a Contributing Science and Technology Editor for BioNews Services, and writes feature-length pieces that draw in some of largest readerships on BioNews websites.

Daniela is a PhD researcher in the field of Clinical Psychology/Psychiatry. Her main fields of interest are Psychopathology and Prevention of Psychotic Disorders in clinical populations, and she brings this expertise to a wide range of different disease-specific websites in the BioNews Services network.

Marueen Newman is a PhD student currently studying biomedical engineering at University of Rochester, specializing in research in biomaterials for drug delivery and regenerative medicine. She is an integral part of Dr. Danielle Benoit’s laboratory, where she is investigating bone-homing therapeutics for osteoporosis treatment.

16

Our content team

ALISA G. WOODS, PhD, M.S. Sr. Science Columnist

Dr. Woods is an Assistant Professor of the Biochemistry & Proteomics Group in the Department of Chemistry & Biomolecular Science at Clarkson University in Potsdam, NY. She serves as a senior science columnist for BioNews Services, typically working on articles on our most high-profile websites and driving high-quality, patient-focused web traffic.

Writers and Editors

PATRICIA SILVA, PhD

PATRICIA INACIO, PhD

ANA PAMPLONA, PhD ISAURA SANTOS

Sr. Science Columnist

Science Columnist

Science Columnist Daily Columnist

KARA ELAM Science Columnist and Event Correspondent

Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

Ana has a PhD in Biochemistry from the Faculty of Science and Technology from Lisbon (UNL), Portugal. She completed her post-doctoral research in Malaria with Prof. Maria Mota for 6 years, and has served as a Staff Scientist in the T cell differentiation and Tumor targeting Lab at Instituto de Medicina Molecular, headed by Prof. Bruno Silva-Santos, where she continued studying malaria pathogenesis.

Kara Elam is currently working on her Doctorate in Health Policy. She holds Master Degrees in both epidemiology and microbiology. Her research interests include emerging viral diseases, the intersection of human rights and intellectual property rights, and ending violence against women.

Isaura Santos graduated with a BS in Cell and Molecular Biology from Universidade Nova de Lisboa and a MA in Communication, Culture and Information Technologies from University Institute of Lisbon (ISCTE-IUL). Her professional interests include science communication, public awareness of science and communication of science through entertainment.

17

Our content team

TERESA PAIS, PhD Science Columnist

Teresa F. Pais holds her PhD in Biomedical Sciences from University of Porto. She has worked in innate immune responses in the context of both infection and neurodegeneration. Currently, she is a researcher at Instituto de Medicina Molecular where she investigates inflammatory processes in the brain.

Writers continued

5307 E. Mockingbird Ln. Fifth Floor Dallas, TX 75206 bionewsservices.com 214.379.7441